THT 2025: SUMMIT: Impact of Obesity Severity on Tirzepatide in HFpEF

THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) show...

- findings showed baseline BMI and baseline waist-to-height ratio didn't impact effect of tirzepatide on primary outcomes in worsening HF and CV death.
- secondary measures: change in 6 min walk distance, changes in CRP and blood pressure, and changes in KCCQ clinical summary score: although differences weren't statistically significant, there was a trend in greater improvement in 6 min w distance and quality of life scores in patients with higher BMI at baseline compared other those with less severe obesity but didn't reach statistical significance
- relationship between change in body weight and waist circumference as a measure of central adiposity: restricted to patients randomized to and received tirzepatide: patients with greater reduction in body weight or greater reduction in waist circumference improvements in quality of life scores and 6 min w d found striking positive correlation - patients with greater reduction in body weight or r

Dr Barry Borlaug (Mayo Clinic and Foundation, Rochester, MN, US) joins us to discuss the findings from SUMMIT (NCT04847557; Eli Lilly and Company), a randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Tirzepatide in patients with HFpEF and obesity. The primary outcome measures were change from baseline in the Kansas City Cardiomyopathy Questionnaire and the occurrence of the composite endpoint of cardiovascular death and/or heart failure events.

- subanalysis
- targeting obesity-related HFpEF with dual GIP GLP1 receptor agonist Tirzepatide could improve HF, reducing risk of worsening HF or CV death in these patients
- impact of baseline obesity severity - relationship between change in body weight and waist circumference as a measure of central adiposity

Interview Questions:
1. What is the reasoning behind the SUMMIT trial?
2. What was the specific focus of this subanalysis, and what were the primary findings?
3. What were the secondary findings?
4. How can the findings of the SUMMIT trial be used to identify patients who would benefit most from tirzepatide?
5. What are the next steps?

Recorded remotely from Minnesota, 2025

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe CVRM.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO